| ID | 1044 |
| Name of the vaccine | Pentacel |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 6 weeks to 4 years |
| Description of the vaccine | Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)(DTaP vaccine). |
| Name of the manufacturer | Sanofi Pasteur Limited and Sanofi Pasteur SA |
| Name of the manufacturing country | Canada and France |
| Year of manufacture | 2008 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | Was based on a comparison of pertussis immune responses following Pentacel in US children to responses following Daptacel. |
| Vaccine formulation | Suspension for injection as a liquid vaccine. |
| Dosage | Four dose immunization series administered at 2, 4, 6 and 15-18 months. |
| Mechanism of action | Not clearly defined. |
| Route of administration | Intramuscular |
| Indications | The safety and effectiveness in infants less than 6 weeks and in children 5 to 16 years have not been established. |
| Export | Distributed by- Sanofi Pasteur Inc. , USA |
| Approval | US FDA |
| Adjuvant | Aluminium phosphate |
| Repurposing | For diphtheria, tetanus, poliovirus and Haemophilus b. |
| Side effects of vaccine | Fussiness, inconsolable crying, fever, tenderness and increase in arm circumference. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT00804284 |
| Reference | https://www.fda.gov/media/74385/download |
| Other name | NA |
| Additional Links | NA
|